BioXcel Therapeutics, Inc. 8-K

What Happened
BioXcel Therapeutics, Inc. announced on July 3, 2026 that it entered into a Tenth Amendment to its Credit Agreement (agent: Oaktree Fund Administration LLC). The lenders agreed to capitalize accrued and unpaid interest through June 30, 2026 (payment-in-kind), defer the principal payment originally due June 30, 2026 until July 31, 2026 (a payment of $9,016,914.47 plus accrued interest and fees will be due then), and reduce the minimum cash liquidity covenant from $12.5 million to $7.5 million. The Company also paid a fee equal to 100 basis points (1.00%) of outstanding loan principal, which was added to the loan principal (paid in kind).

Key Details

• Amendment effective July 3, 2026: accrued interest through June 30, 2026 capitalized; June 30 principal deferred to July 31, 2026 with $9,016,914.47 due then (plus interest/fees).
• Liquidity covenant lowered to $7.5 million (from $12.5 million).
• Company must, on or prior to July 31, 2026, enter into definitive agreements that either (A) repay all credit obligations or (B) provide alternative capital solutions acceptable to lenders.
• Lenders may transfer or assign loans to third parties; the Company waived contractual restrictions that would block such transfers.
• The Company must create a strategic process committee (comprised solely of David Mack or another independent director acceptable to lenders) with exclusive authority to evaluate and implement any sale, restructuring, equity raise, insolvency filing or similar material transaction.
• Additional operating controls: weekly meetings with lenders and financial advisors, bi‑weekly delivery of a 13‑week cash flow budget, a cap preventing disbursements above 115% of the two‑week budgeted amount, limitations on dividends, investments, asset dispositions, incurrence of new debt, and a freeze on compensation changes through July 31, 2026.

Why It Matters
The amendment gives BioXcel short-term relief (interest capitalized and a brief principal deferral, plus a lower minimum liquidity threshold) but also imposes stricter lender controls and operational limits. Investors should note the near-term cash event on July 31, 2026 (the ~ $9.0M payment plus interest/fees) and the requirement to secure a repayment or alternative financing by that date. The establishment of a lender‑approved strategic process committee and broadened loan assignment rights increase the likelihood that lenders could drive or approve a sale, restructuring, or other transaction if needed. These changes signal lender concern about liquidity and give lenders greater oversight of major corporate actions.